8-K: Silexion Therapeutics Unveils SIL204 for Pancreatic Cancer

Silexion Therapeutics Corp. presented its next-generation RNAi therapeutic, SIL204, targeting KRAS mutations in historically undruggable cancers, with Phase 2/3 trials for pancreatic cancer set to begin in Q2 2026.

Summary

• Silexion Therapeutics Corp. filed an 8-K with a corporate presentation for use in meetings with investors as part of a non-deal roadshow.
• The company's lead product, SIL204, is a first-in-class, isoform-selective, pan KRAS silencer, stable siRNA with a targeted delivery system.
• SIL204 targets the mutated KRAS gene, a common oncogenic driver in human cancers, present in 92% of Pancreatic Ductal Adenocarcinoma (PDAC), 49% of Colorectal Cancer (CRC), and 35% of Non-squamous Non-Small-Cell Lung Cancer (Non-sq NSCLC).
• A dual-delivery strategy for SIL204 (intratumoral and systemic) is designed to effectively treat both primary tumors and metastases.
• First-generation product (LODER) Phase 2 clinical trial data showed a trend for extending overall survival in locally advanced pancreatic cancer (LAPC) patients by 9.3 months (median 22.7 months with LODER+SOC chemo vs. 13.4 months with SOC chemo alone).
• LODER was generally well tolerated with no related Treatment Emergent Adverse Events (TEAEs) and no safety concerns from the Independent Drug Safety Monitoring Board (DSMB).
• SIL204 demonstrates high effectiveness and broad inhibition across human KRAS mutations (G12D, G12V, G12C, G12R, Q61H, G13D) at sub-nanomolar concentrations (IC50 values ranging from 0.16 nM to 0.59 nM).
• Preclinical data shows intratumoral SIL204 significantly reduced tumor volume and growth while increasing tumor necrosis in human pancreatic cancer xenografts.
• Systemic SIL204 remains at substantial levels for over 56 days in target tissues in rats, suggesting potential for monthly subcutaneous dosing to treat micrometastases.
• SIL204's anti-tumor activity is synergistic with pancreatic cancer chemotherapy.
• Extended single-dose GLP toxicity studies completed in two relevant species established safety margins up to 11-fold over the clinical starting dose, with no systemic toxicity or organ damage observed.
• The Phase 2/3 clinical trial for SIL204 in LAPC is planned for initiation in Q2 2026, with overall survival (OS) as the primary endpoint.
• Patent protection for SIL204 as a composition and for use in treatment of pancreatic and other cancers is expected until 2043, with an estimated extension to 2048.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, highlighting promising preclinical and early clinical data for SIL204 in a high-unmet-need area, coupled with a clear development pathway. However, the company remains development-stage with significant future risks.

Positives

• First-generation LODER showed a 9.3-month improvement in median overall survival for LAPC patients (22.7 months vs. 13.4 months for SOC chemo), indicating a positive trend.
• LODER was generally well tolerated with no related Treatment Emergent Adverse Events (TEAEs) in its Phase 2 trial.
• SIL204 is a first-in-class, isoform-selective, pan KRAS silencer with a targeted delivery system, addressing a significant unmet medical need.
• SIL204 demonstrates high effectiveness and broad inhibition across various human KRAS mutations at sub-nanomolar concentrations in preclinical studies.
• Preclinical data shows significant tumor volume reduction and increased necrosis with intratumoral SIL204 in human pancreatic cancer xenografts.
• Systemic SIL204 shows potential for treating micrometastases with monthly dosing, remaining at substantial levels for over 56 days in target tissues.
• SIL204's anti-tumor activity is synergistic with pancreatic cancer chemotherapy.
• GLP toxicity studies show favorable tolerability with safety margins up to 11-fold over the clinical starting dose and no systemic toxicity or organ damage.
• Strong intellectual property protection for SIL204 is expected until 2043, with potential extension to 2048.
• Collaboration with leading European manufacturers, Catalent and Axolabs, for GMP clinical supply enhances SIL204's development.
• The company has a highly experienced leadership team and a world-renowned expert scientific advisory board.

Negatives

• Silexion is a development-stage company with a limited operating history.
• The company has never generated any revenue from product sales and may never be profitable.
• The RNAi therapeutic approach for oncology is unproven and may not lead to marketable products.
• Silexion lacks experience producing product candidates at commercial levels, has no marketing and sales organization, and faces uncertain market receptiveness and insurance coverage/reimbursement.
• There is a risk of being unable to attract, develop, and/or retain key personnel.
• The overall survival improvement observed with the first-generation LODER was a 'trend' (p=0.39), not statistically significant, requiring further validation.

Risks

• Silexion is a development-stage company and has a limited operating history on which to assess its business.
• Silexion has never generated any revenue from product sales and may never be profitable.
• The approach Silexion is taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
• Silexion does not have experience producing its product candidates at commercial levels, currently has no marketing and sales organization, has an uncertain market receptiveness to its product candidates, and is uncertain as to whether there will be insurance coverage and reimbursement for its potential products.
• Silexion may be unable to attract, develop and/or retain its key personnel or additional employees required for its development and future success.
• Actual results or performance may be materially different from forward-looking statements due to various risks and uncertainties.

Future Outlook

Silexion plans to initiate its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer in Q2 2026, with the safety run-in expected to complete by Q4 2026, followed by Phase 2 expansion and Phase 3 confirmatory trials in Q3 2028. The company also plans to expand trials to the US, Canada, UK, additional EU countries, and Australia, and aims to complete the toxicology package for marketing approval in H2 2026.

Management Comments

• Our forward-looking statements include, but are not limited to, statements regarding our or our management teams expectations, hopes, beliefs, intentions or strategies regarding the future.
• We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Industry Context

StockSavvy.ai notes that Silexion's focus on KRAS mutations addresses a significant unmet need in oncology, particularly in pancreatic cancer, which is notoriously difficult to treat and has a high prevalence of KRAS mutations. While small molecule RAS inhibitors are emerging, Silexion's siRNA approach offers a distinct mechanism of action by silencing the oncogene at the gene expression level, potentially providing a differentiated therapeutic option in a competitive but underserved market.

Comparison to Industry Standards

• Median survival for locally advanced pancreatic cancer (LAPC) is typically 14-17 months, as cited from Gemenetzis G, et al. Ann Surg. 2019;270(2):340-347 and Alagesan, B. et al. AARC 2026. Silexion's first-generation LODER showed a median overall survival of 22.7 months in Cohort 1, compared to 13.4 months for standard of care (SoC) chemo, suggesting a potential improvement over current benchmarks.
• New small molecule RAS inhibitors, such as those from Revolution Medicines (November 2025 Company Presentation), show promising efficacy and acceptable safety, but Silexion's siRNA approach targets both active and inactive forms of KRAS and uses a dual-delivery strategy, potentially offering broader activity and improved delivery compared to single-target small molecules.

Stakeholder Impact

• Shareholders: Potential for significant value creation if SIL204 successfully navigates clinical trials and gains regulatory approval, addressing a large unmet medical need. However, high risk due to the development-stage nature of the company and unproven RNAi approach in oncology.
• Patients: Potential for a novel and effective treatment option for historically undruggable cancers, particularly locally advanced pancreatic cancer, which currently has very poor prognoses.
• Employees: Continued employment and potential growth opportunities as the company progresses through clinical development.
• Regulatory Authorities: Will closely monitor the safety and efficacy data from ongoing and planned clinical trials for a novel RNAi therapeutic.

Next Steps

• Initiation of SIL204 Phase 2/3 safety run-in in Q2 2026.
• Completion of toxicology package for marketing approval in H2 2026.
• Completion of Phase 2/3 safety run-in in Q4 2026.
• Initiation of Phase 2 expansion in Q4 2026.
• Submission to German MoH for Phase 2/3 trial planned for February 2026.
• IND and CTA for additional EU countries, submission planned Q4/2026-Q1/2027.
• Start expanding trial to US, Canada, UK, additional EU countries, Australia.
• Initiation of Phase 3 confirmatory trial in Q3 2028.
• Trial interim results and sample size adjustment in 2028.

Key Dates

Recommendation

Silexion Therapeutics presents promising preclinical data for SIL204 and encouraging, albeit not statistically significant, Phase 2 results for its first-generation product in a challenging cancer. The clear roadmap for Phase 2/3 trials and strong intellectual property are positives. However, the company is still in early-to-mid-stage development, has no revenue, and faces significant risks inherent in drug development, particularly with an unproven RNAi approach in oncology. A "hold" recommendation is appropriate for seasoned investors to monitor the progress of the Phase 2/3 trials and further de-risking of the technology before considering a stronger position.

Keywords

Silexion Therapeutics, SLXN, RNAi, siRNA, KRAS, pancreatic cancer, oncology, targeted therapy, gene silencing, drug development, clinical trials, LAPC, colorectal cancer, non-small cell lung cancer, biotechnology, pharmaceuticals